| |
Non-compliant N=46 |
Compliant N=43 |
p-value |
| Median age, yrs (IQR) |
36 (27) |
38 (21) |
0.88 |
| Female (%) |
52.4 |
47.6 |
0.70 |
| African American or Afro-Caribbean (%) |
55.8 |
44.2 |
0.82 |
| Solely Spanish speaking (%) |
30.0 |
70.0 |
0.18* |
| Education above High School (%) |
59.5 |
40.5 |
0.06* |
| Income <$15,000 (%) |
54.5 |
45.5 |
0.13* |
| Medicare/Private Insurance (%) |
57.1 |
42.9 |
0.49 |
| Disease Duration, yrs (IQR) |
9 (12) |
7 (11) |
0.22 |
| SLEDAI, points (IQR) |
2 (2) |
3 (5) |
0.37 |
| Mycophenolate mofetil use (%) |
75.0 |
25.0 |
0.12* |
| Other DMARD use (%) |
57.1 |
42.9 |
0.51 |
| Hydroxychloroquine use (%) |
47.8 |
52.2 |
0.19* |
| Self reported as compliant (miss medications < 1x/week) (%) |
51.7 |
48.3 |
0.87 |
| Mean BMQ concerns score (±SD) |
14.5 (0.62) |
12.3 (0.60) |
0.02* |
| Median BMQ necessity score (±SD) |
10.8 (3.9) |
11.0 (4.1) |
0.82 |
| Side effects ≥ 1x/wk (%) |
44.1 |
55.9 |
0.18* |
| *These variables where included in the multivariate analysis to determine which of the above were most associated with compliance when adjusting for other variables. |
